sorafenib has been researched along with Liver Dysfunction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Capelletti, MM; Manceau, H; Peoc'h, K; Puy, H | 1 |
| Biswas, S; Ghose, S; Ghufran, SM; Sharma, S | 1 |
| Pár, A; Pár, G | 1 |
| Smilde, T; Toonen, F | 1 |
| Fabris, L; Ferrero, C; Fiorotto, R; Kim, AK; Locatelli, L; Morell, CM; Okolicsanyi, S; Spirli, C; Strazzabosco, M | 1 |
| Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS | 1 |
1 review(s) available for sorafenib and Liver Dysfunction
| Article | Year |
|---|---|
Ferroptosis in Liver Diseases: An Overview.
Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cysteine; Ferroptosis; Glutathione; Heme; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Lipoxygenase; Liver Diseases; Liver Neoplasms; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction; Sorafenib; Spiro Compounds; Sulfasalazine; Tumor Suppressor Protein p53 | 2020 |
5 other study(ies) available for sorafenib and Liver Dysfunction
| Article | Year |
|---|---|
Cytoplasmic vacuolation with endoplasmic reticulum stress directs sorafenib induced non-apoptotic cell death in hepatic stellate cells.
Topics: Calreticulin; Caspase Inhibitors; Cell Death; Cell Line; Cell Survival; Cytoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Heat-Shock Proteins; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Liver Diseases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction; Sorafenib; Vacuoles; X-Box Binding Protein 1 | 2021 |
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib | 2008 |
A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Hepatocellular; Choristoma; Diagnosis, Differential; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retroperitoneal Neoplasms; Retroperitoneal Space; Sorafenib; Testicular Neoplasms; Ultrasonography | 2010 |
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzenesulfonates; Bile Ducts; Caspase 3; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Cysts; Drug Therapy, Combination; Epithelial Cells; Ki-67 Antigen; Liver Diseases; MAP Kinase Signaling System; Mice; Mice, Knockout; Niacinamide; Octreotide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib; TRPP Cation Channels | 2012 |
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.
Topics: Animals; Benzenesulfonates; Common Bile Duct; Disease Models, Animal; Hemodynamics; Hepatopulmonary Syndrome; Ligation; Liver; Liver Cirrhosis, Biliary; Liver Diseases; Lung; Male; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |